{"title":"Economic factors hamper HIV control efforts.","authors":"Keith Henry","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"24 1","pages":"2-3"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"HIV treatment as prevention--the time is now.","authors":"Charles B Hicks","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"24 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Growing the intense inhibitor class--Elvitegravir and Dolutegravir.","authors":"Charles B Hicks","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"24 1","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-01-01DOI: 10.1056/AC201207090000001
D. Kuritzkes
In June 2012, researchers and physicians from around the world gathered in Sitges, Spain, for the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Below is a summary of the most clinically compelling presentations with respect to HIV medicine. (The entire abstract book is available in a supplement of Antiviral Therapy.) Resistance to Integrase Inhibitors: Raltegravir, Elvitegravir, and Dolutegravir Elvitegravir is an investigational integrase inhibitor currently being evaluated by the FDA, both individually and as part of the coformulated Quad pill. Previous studies identified six positions in integrase that are important for elvitegravir resistance, several of which are also important for raltegravir and, to a lesser extent, dolutegravir. In two separate industry-funded studies, Michael Abram, Kirsten White, and colleagues evaluated mutations that occurred at the time of elvitegravir failure [Abstracts 3 and 4]. They found extensive overlap in resistance patterns between elvitegavir and raltegravir, with considerable cross-resistance, even though the specific mutations commonly selected by each drug differed somewhat. For example, the Q148H mutation seems most important for raltegravir, but it was the Q148R mutation that gave the biggest effect for elvitegravir, followed by mutations at positions 92, 155, and 66. Furthermore, in a comparison of the Quad pill with Atripla (tenofovir/FTC/efavirenz), the researchers found that resistance to elvitegravir at the time of treatment failure was just as common as resistance to efavirenz. Although failure is uncommon with these regimens, resistance is likely to occur in about half of the failures. This is in stark contrast to boosted protease inhibitor–based regimens, where resistance is rarely seen at the time of failure. Not far behind elvitegravir in the pipeline is dolutegravir, which has broader activity than elvitegravir and is active against both elvitegravir- and raltegravir-resistant virus. In the industry-sponsored, single-arm VIKING-II study, patients with raltegravir-resistant virus …
{"title":"Report from the 2012 International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies.","authors":"D. Kuritzkes","doi":"10.1056/AC201207090000001","DOIUrl":"https://doi.org/10.1056/AC201207090000001","url":null,"abstract":"In June 2012, researchers and physicians from around the world gathered in Sitges, Spain, for the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Below is a summary of the most clinically compelling presentations with respect to HIV medicine. (The entire abstract book is available in a supplement of Antiviral Therapy.) Resistance to Integrase Inhibitors: Raltegravir, Elvitegravir, and Dolutegravir Elvitegravir is an investigational integrase inhibitor currently being evaluated by the FDA, both individually and as part of the coformulated Quad pill. Previous studies identified six positions in integrase that are important for elvitegravir resistance, several of which are also important for raltegravir and, to a lesser extent, dolutegravir. In two separate industry-funded studies, Michael Abram, Kirsten White, and colleagues evaluated mutations that occurred at the time of elvitegravir failure [Abstracts 3 and 4]. They found extensive overlap in resistance patterns between elvitegavir and raltegravir, with considerable cross-resistance, even though the specific mutations commonly selected by each drug differed somewhat. For example, the Q148H mutation seems most important for raltegravir, but it was the Q148R mutation that gave the biggest effect for elvitegravir, followed by mutations at positions 92, 155, and 66. Furthermore, in a comparison of the Quad pill with Atripla (tenofovir/FTC/efavirenz), the researchers found that resistance to elvitegravir at the time of treatment failure was just as common as resistance to efavirenz. Although failure is uncommon with these regimens, resistance is likely to occur in about half of the failures. This is in stark contrast to boosted protease inhibitor–based regimens, where resistance is rarely seen at the time of failure. Not far behind elvitegravir in the pipeline is dolutegravir, which has broader activity than elvitegravir and is active against both elvitegravir- and raltegravir-resistant virus. In the industry-sponsored, single-arm VIKING-II study, patients with raltegravir-resistant virus …","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"55 1","pages":"63-5"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74103177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-01-01DOI: 10.1056/AC201112300000013
R. Gandhi
For several years, an interesting story has been emerging that links persistent immune activation in HIV-infected patients with non–AIDS-related complications and, potentially, accelerated aging. In 2011, several new chapters were added to this fascinating narrative. A large epidemiologic study found that, compared with HIV-uninfected individuals, HIV-infected patients had higher rates of chronic diseases typical of aging, including kidney disease, diabetes, bone fracture, and cardiovascular disease. The risk for multiple concurrent comorbidities was about the same for a 40-year-old HIV-infected …
{"title":"HIV-related immune activation and non-AIDS-related complications: story unfolds.","authors":"R. Gandhi","doi":"10.1056/AC201112300000013","DOIUrl":"https://doi.org/10.1056/AC201112300000013","url":null,"abstract":"For several years, an interesting story has been emerging that links persistent immune activation in HIV-infected patients with non–AIDS-related complications and, potentially, accelerated aging. In 2011, several new chapters were added to this fascinating narrative. A large epidemiologic study found that, compared with HIV-uninfected individuals, HIV-infected patients had higher rates of chronic diseases typical of aging, including kidney disease, diabetes, bone fracture, and cardiovascular disease. The risk for multiple concurrent comorbidities was about the same for a 40-year-old HIV-infected …","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"455 1","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79758483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Special feature. Year in review 2011.","authors":"Paul E Sax","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"24 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cure: no longer a four-letter word in HIV research.","authors":"Rajesh T Gandhi","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"24 1","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"HIV continues to target young black MSM ...and syphilis isn't far behind.","authors":"Abigail Zuger","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"24 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：